Fig 1: Pmm2R137H/F115L mice have significantly altered levels of disease-relevant plasma biomarkers. (A) Mean (±SD) levels of ATIII, IGF-1 and IGFBP-3 measured by ELISA in plasma of Pmm2WT/WT (n = 21), Pmm2R137H/WT or Pmm2F115L/WT (n = 20) and Pmm2R137H/F115L (n = 7) mice. P-values were generated using one-way ANOVA test followed by Tukey post-hoc tests for multiple comparisons. (B) Glycosylation and expression level of ALS and transferrin in mouse plasma (genotype indicated above, hypomorphic mutants labeled in red). The two lanes on the far right are controls. Glycosylated control was a sample of normal B6 mouse plasma. Deglycosylated control was a sample of normal B6 mouse plasma de-glycosylated in vitro by N-glycanase. Note an increase in migration rate for both ALS and transferrin after N-glycanase treatment. (C) Mean (±SD) levels of PTX3 and IGFBP-1 measured by ELISA in plasma of Pmm2WT/WT (n = 21), Pmm2R137H/WT or Pmm2F115L/WT (n = 20) and Pmm2R137H/F115L (n = 7) mice. P-values were generated using one-way ANOVA test followed by Tukey post-hoc tests for multiple comparisons.